Mark A Glickman
CIK 1441461 · Co-Chief Executive Officer · last filed 2026-08-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AUXL price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
545 CONCORD AVENUE, SUITE 210
CAMBRIDGE, MA 02138
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) Delisted | Director | 7,671 | $1.56 | $12.0K | $0 | 1 | 2026-08-28 |
| MetaVia Inc. (NRBO) Delisted | Director | 20,629 | $2.36 | $48.7K | $0 | 4 | 2026-06-08 |
| TXMD | Co-Chief Executive Officer | 1,734 | $1.81 | $3.1K | -$2.2K | 4 | 2022-12-09 |
| Esperion Therapeutics, Inc. (ESPR) Delisted | Chief Commercial Officer | 25,925 | $3.18 | $82.4K | $0 | 1 | 2020-01-03 |
| Aralez Pharmaceuticals Inc. (ARLZ) Delisted | Chief Commercial Officer | 250,188 | — | — | $82.3K | 7 | 2018-03-21 |
| POZEN INC /NC (POZN) Delisted | Chief Commercial Officer | 29,137 | — | — | $0 | 1 | 2015-06-24 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | EVP - Sales and Marketing | 0 | — | — | -$1.59M | 10 | 2015-01-30 |
| OSCIENT PHARMACEUTICALS CORP (OSCI) Delisted | SVP, Sales & Marketing | 36,157 | — | — | $0 | 1 | 2008-07-30 |
Recent Filings · Page 2 of 3
29 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-03-21 | Aralez Pharmaceuticals Inc. (ARLZ) Delisted | Sell (S) | −5,725 | -$9.7K | EDGAR |
| 2017-05-12 | Aralez Pharmaceuticals Inc. (ARLZ) Delisted | Grant (A) | +80,163 | $0 | EDGAR |
| 2016-06-24 | Aralez Pharmaceuticals Inc. (ARLZ) Delisted | Tax (F) | −10,803 | -$36.1K | EDGAR |
| 2016-05-18 | Aralez Pharmaceuticals Inc. (ARLZ) Delisted | Buy (P) | +25,000 | $92.0K | EDGAR |
| 2016-03-18 | Aralez Pharmaceuticals Inc. (ARLZ) Delisted | Grant (A) | +45,553 | $0 | EDGAR |
| 2016-02-17 | Aralez Pharmaceuticals Inc. (ARLZ) Delisted | Grant (A) | +86,863 | $0 | EDGAR |
| 2016-02-09 | Aralez Pharmaceuticals Inc. (ARLZ) Delisted | Other (J) | +29,137 | $0 | EDGAR |
| 2015-06-24 | POZEN INC /NC (POZN) Delisted | Grant (A) | +29,137 | $0 | EDGAR |
| 2015-01-30 | AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | Other (J) | −27,911 | -$1.02M | EDGAR |
| 2014-11-24 | AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | Mixed | −7,202 | -$753.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.